4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

8-K - CervoMed Inc. (0001053691) (Filer)

8-K - CervoMed Inc. (0001053691) (Filer)

S-8 - CervoMed Inc. (0001053691) (Filer)

10-Q - CervoMed Inc. (0001053691) (Filer)

8-K - CervoMed Inc. (0001053691) (Filer)

8-K - CervoMed Inc. (0001053691) (Filer)

8-K - CervoMed Inc. (0001053691) (Filer)

8-K - CervoMed Inc. (0001053691) (Filer)

8-K - CervoMed Inc. (0001053691) (Filer)

10-Q - CervoMed Inc. (0001053691) (Filer)

Chardan Capital Markets upgraded CervoMed from Neutral to Buy and set a new price target of $14.00

H.C. Wainwright downgraded CervoMed from Buy to Neutral

Chardan Capital Markets downgraded CervoMed from Buy to Neutral

Morgan Stanley downgraded CervoMed from Overweight to Underweight

D. Boral Capital downgraded CervoMed from Buy to Hold

ROTH MKM initiated coverage of CervoMed with a rating of Buy and set a new price target of $45.00

H.C. Wainwright initiated coverage of CervoMed with a rating of Buy and set a new price target of $42.00

Chardan Capital Markets initiated coverage of CervoMed with a rating of Buy and set a new price target of $55.00

Morgan Stanley initiated coverage of CervoMed with a rating of Overweight and set a new price target of $35.00

Canaccord Genuity initiated coverage of CervoMed with a rating of Buy and set a new price target of $50.00

4 - CervoMed Inc. (0001053691) (Issuer)

3 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggesting neflamapimod may act on underlying disease CervoMed preparing to initiate Phase 3 registrational trial in patients with DLB in the second half of 2026 BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Today in a late-breaking oral session at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego, California, clinical investigators shared the full results of the Phase 2b RewinD-LB trial of neflamapimod, being developed by C

1st of two presentations with results from Phase 2b study of neflamapimod at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary acidic protein (GFAP), a key marker of neuroinflammation-associated neurodegeneration, and increased beta amyloid (A) 42/40 ratio in DLB Correlation of the effects of neflamapimod on plasma GFAP with positive treatment response, as assessed by CDR-SB, support neflamapimod mechanism of action and suggest it may act on underlying disease BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company devel

Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB) Reported 32-week data from Phase 2b RewinD-LB trial showing neflamapimod treatment in patients with DLB had a durable beneficial effect on clinical progression and resulted in substantial reductions in plasma levels of a well-established biomarker of neurodegeneration Meeting with global regulators in coming months and preparing for global pivotal trial initiation in second half of 2026 Initial biomarker data from Phase 2a trial in a sub-type of frontotemporal dementia (FTD) and topline results from Phase 2a trial in recovery aft

FDA feedback enables CervoMed to proceed with proposed endpoints, patient enrichment strategy, and other key aspects of Phase 3 trial design to support potential New Drug Application CervoMed is advancing preparations for global pivotal trial initiation in the second half of 2026 BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced it has received written feedback from the U.S. Food and Drug Administration (FDA) aligning on key aspects of CervoMed's proposed Phase 3 clinical trial of neflamapimod, an oral, small molecule, drug candidate

Mr. Quigley most recently led McKinsey & Company's Private Capital practice and previously led various Life Sciences practices at the firm Appointment adds deep business strategy, transactional, and commercial expertise as CervoMed prepares for Phase 3 and commercialization planning BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced the appointment of David Quigley to its Board of Directors (Board). Mr. Quigley is a seasoned executive and former Senior Partner at McKinsey & Company, where he led the firm's Life Sciences and Private Eq

MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 87th Emerging Growth Conference on October 22 & 23, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayOctober 22, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back t

MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 87th Emerging Growth Conference on October 22 & 23, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayOctober 22, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go ba

BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Matthew Winton, Ph.D., Chief Commercial and Business Officer, will present at the Emerging Growth Conference, being held virtually on Wednesday, October 22, 2025. Presentation DetailsFormat: Corporate PresentationDate: Wednesday, October 22, 2025Time: 11:25 – 11:55 AM ETWebcast Link: https://goto.webcasts.com/starthere.jsp?ei=1717092&tp_key=1ddfafa563&sti=crvo The webcast and replay of the presentation will be accessible in the Investor section of the CervoMed website https://w

Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low likelihood of having Alzheimer's disease (AD) co-pathology Significant reduction in plasma levels of a well-established biomarker of neurodegeneration, plasma glial fibrillary acidic protein (GFAP), correlated to treatment response assessed by CDR-SB CervoMed anticipates U.S. Food and Drug Administration (FDA) feedback on Phase 3 trial design in the fourth quarter of 2025 BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treat

BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Dr. Winton joins CervoMed with nearly two decades of experience in the global biotechnology industry, leading organizations through scientific breakthroughs, growth and innovation, and market transformation. "It is a pleasure to welcome Matthew, an experienced and proven leader and organization builder," said John Alam, M.D., Chief Executive Officer of CervoMed. "This appointment comes at a pivotal ti

Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB) Reported 32-week data from Phase 2b RewinD-LB trial showing neflamapimod treatment in patients with DLB had a durable beneficial effect on clinical progression and resulted in substantial reductions in plasma levels of a well-established biomarker of neurodegeneration Meeting with global regulators in coming months and preparing for global pivotal trial initiation in second half of 2026 Initial biomarker data from Phase 2a trial in a sub-type of frontotemporal dementia (FTD) and topline results from Phase 2a trial in recovery aft

Mr. Quigley most recently led McKinsey & Company's Private Capital practice and previously led various Life Sciences practices at the firm Appointment adds deep business strategy, transactional, and commercial expertise as CervoMed prepares for Phase 3 and commercialization planning BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced the appointment of David Quigley to its Board of Directors (Board). Mr. Quigley is a seasoned executive and former Senior Partner at McKinsey & Company, where he led the firm's Life Sciences and Private Eq

BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Dr. Winton joins CervoMed with nearly two decades of experience in the global biotechnology industry, leading organizations through scientific breakthroughs, growth and innovation, and market transformation. "It is a pleasure to welcome Matthew, an experienced and proven leader and organization builder," said John Alam, M.D., Chief Executive Officer of CervoMed. "This appointment comes at a pivotal ti

BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will continue as a consultant to CervoMed following the transition. "Bill's deep biopharmaceutical and financial expertise and strong track record of enhancing operational capabilities makes him

- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of 2025 - CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024 - Integrated summary of results from AscenD-LB Phase 2a trial published in peer-reviewed journal and presentations at a major scientific conference further inform on the potential of neflamapimod in DLB and proba

Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical comp

Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of treatment (p=0.0037). This risk reduction improved to 64% (p=0.0001) among patients who have minimal evidence of AD co-pathology (ptau181 < 2.2 pg/mL at screening) At week 32 of the Extension phase, patients treated with neflamapimod demonstrated a significant reduction from baseline in plasma levels of glial fibrillary acidic protein (GFAP) Conference call and webcast today at 8:00 AM ET today to discuss results BOSTON, July 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc

Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference® (AAIC) 2025 Conference call and webcast to be held Monday, July 28 at 8:00 AM ET BOSTON, July 24, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company will host a conference call and webcast on Monday, July 28 at 8:00 AM ET to share new results, including the primary endpoint results at 32-weeks of the Extension phase, from the Phase 2b RewinD-LB study of neflamapimod in dementia with Lewy bod

A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Improvement (p=0.035 against either old capsules or placebo) also demonstrated on the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (CGIC) Compared to either old capsules or placebo, a lower incidence of falls was seen in participants receiving study drug from the new batch of capsules during the extension phase Company to host investor webcast at 5:00 PM ET today to discuss results BOSTON, March 10,

SC 13G - CervoMed Inc. (0001053691) (Subject)

SC 13G - CervoMed Inc. (0001053691) (Subject)

SC 13G/A - CervoMed Inc. (0001053691) (Subject)

SC 13D/A - CervoMed Inc. (0001053691) (Subject)